Company’s PPD clinical research business to share expertise in recruiting diverse patient populations
Hanover, MD, May 3, 2022 – The Society for Clinical Research Sites (SCRS) today announced that Thermo Fisher Scientific Inc., the world leader in serving science, has made a commitment through its PPD clinical research business to become an Oncology Spirit Partner and a funding sponsor of the SCRS Diversity Awareness Program. Oncology Spirit Partners serve on the SCRS Oncology Advisory Board and take leadership roles in the SCRS Oncology Program and Strategic Working Groups. Spirit Partners are actively involved in the annual SCRS Global Oncology Site Solutions Summit, including exhibiting, speaking and hosting a Site Partnership Symposium.
“SCRS Oncology Spirit Partners are vital to helping SCRS address issues that oncology sites are facing today,” commented Marcus Malek, SCRS Director of Global Business Partnerships. “SCRS is eager to showcase the PPD clinical research business’ valuable expertise as an Oncology Spirit Partner as we work together to increase the efficiency and effectiveness of oncology clinical research sites globally.”
Through the Diversity Awareness Program, SCRS has not only helped sites explore and understand the factors that drive successful recruitment of diverse patient populations but also created an assessment tool to guide sites in improving their ability to recruit diverse patient populations. The PPD clinical research business will be integrated with the SCRS Diversity Program’s working group of supporters to establish best site practices for diverse patient engagement in clinical research, as well as engaging directly with sites via SCRS webinars, summits and publications.
Diana Foster, VP of Strategy and Special Projects for SCRS commented, “The PPD clinical research business has been a valued contributor to SCRS for several years and has consistently demonstrated their commitment to site sustainability. Their engagement in this program will directly support ongoing research that will aid sites in recruiting and engaging diverse patients. SCRS looks forward to collaborating with them to address this industry-wide need.”
“It’s vital that clinical trials include participation by patients representing the diversity of the overall population to ensure the efficacy and effectiveness of promising new treatments for all people,” said David M. Johnston, Ph.D., Senior Vice President and President, Clinical Research, Thermo Fisher Scientific. “Through our collaboration with SCRS, we are able to exchange best practices and hear the ‘voice of the site’ to continually improve trial conduct strategy and execution on behalf of customers and for patients in need.”
Last year, the PPD clinical research business was named the winner of SCRS’ prestigious Eagle Award for its commitment to advancing clinical research professionalism through strong site partnerships. The award, based on voting by research sites globally, recognizes the clinical research organization that best exemplifies a site-focused approach to clinical trial management by demonstrating outstanding leadership, professionalism and integrity.
About The Society for Clinical Research Sites
Founded in 2012, SCRS is a global organization that unifies the voice of the clinical research site community to create greater site sustainability. Representing over 9,500 sites in 47 countries, SCRS membership provides sites with a community dedicated to advocacy, education, mentorship and connectivity. SCRS is an influential voice for sites and an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Our Voice. Our Community. Your Success. Join the community. Visit MySCRS.org.
Society for Clinical Research Sites